Home > News > Autoimmune Comorbid Conditions in Multiple Sclerosis
Multiple Sclerosis
Read Time: 10 mins

Autoimmune Comorbid Conditions in Multiple Sclerosis

Published Online: March 14th 2012 US Neurology, 2011;7(2):132-8 DOI: http://doi.org/10.17925/USN.2011.07.02.132
Authors: Regina Berkovich, Dawood Subhani, Lawrence Steinman
Quick Links:
Abstract
Article
Article Information
Abstract:
Overview

Autoimmune comorbidities occur frequently in multiple sclerosis (MS). They may arise as a consequence of a genetic susceptibility to autoimmunity. Certain pathological mechanisms are common to several autoimmune conditions. In the presence of comorbid autoimmune conditions, certain MS therapeutics may be preferable to others. Autoimmune comorbidity associated with MS could be a factor in predicting response to specific MS therapeutics. Treatment with interferon beta has been reported to precipitate immune-mediated abnormalities or to exacerbate existing autoimmune diseases. In comparison, there are fewer reported cases of treatment-associated comorbidities linked with autoimmune disease in patients taking glatiramer acetate. Knowledge of the factors influencing autoimmune comorbidities may provide insights into the complex pathogenesis of MS and help inform treatment choices.

Keywords

Autoimmune, comorbidity, glatiramer acetate, interferon, multiple sclerosis

Article:

Multiple sclerosis (MS) is the most common inflammatory demyelinating disease of the central nervous system (CNS). Although it is generally considered to be an autoimmune disease, MS may be a heterogeneous condition incorporating different pathologies. The incidence of autoimmune comorbidities in MS patients may help us elucidate the autoimmune aspects of the disease. Furthermore, the presence of autoimmune comorbidities may help us discover new biomarkers with potential predictive value regarding response to treatment, and understand common factors in pathogenesis. This article aims to review autoimmune comorbidities in MS, their incidence and burden in the MS population, and their possible association with MS treatments. We will address potential measures that might reduce the impact of treatment in triggering comorbidities.

Multiple Sclerosis as an Autoimmune Disease
The most widely accepted hypothesis for the pathogenesis of MS is that it is a primary autoimmune disease. This idea was reinforced following observations on experimental autoimmune encephalomyelitis (EAE) in the late 1960s and early 1970s.1–4 It has been repeatedly demonstrated that EAE is an autoimmune disorder caused by T-cell sensitization to various myelin proteins capable of triggering encephalomyelitis. The hypothesis is further supported by considerable evidence, such as the presence of elevated lymphocytes, macrophages, and microglia in MS lesions; strong genetic associations with genes in the major histocompatibility complex (MHC) region of chromosome 6; and the efficacy of new treatments that target the immune response. However, there are some aspects of the autoimmune pathogenesis hypothesis of MS that require further clarification. Much of this hypothesis is based on animal models of EAE; however, many agents that can successfully treat EAE have failed to show any clinical benefit in MS. This suggests that EAE is not an accurate model of MS and that the two conditions have some different pathophysiological characteristics.5 In order to yield clues to the pathogenesis of MS, EAE experimental models should be critically coupled with actual findings in MS.6

The most compelling evidence that there is an immune pathogenesis in MS comes from the striking benefit seen when lymphocyte migration to the CNS is blocked with natalizumab, or when lymphocytes are trapped n regional lymph nodes with fingolimod.7,8 It is difficult to discount the fact that, when monocytes are barred entry to the CNS, the rate of elapse and pace of progression of disability in MS are attenuated.

A further challenge to the autoimmune pathogenesis hypothesis of MS has arisen following findings that some of the antibodies identified in the cerebrospinal fluid of MS patients are not directed against any of the known myelin proteins.9 A mitigating argument is that some of these antibodies may be targeting myelin lipids and carbohydrates that are known to play a role in autoimmune inflammation.10 One hypothesis is that demyelination is caused by oligodendrologlial apoptosis and that inflammation is merely a secondary event initiated to eliminate the products of myelin degeneration.11 Whether it is apoptosis or infection that triggers the inflammatory response, there is evidence of an unmistakable immune footprint at the site of disease. Inhibiting the entry of immune cells to the brain provides great benefit, as shown by natalizumab, its effects, and its underlying mechanism of action.7

Another confounding factor in the pathogenesis of MS lies in the available treatment options. MS relapse management treatments, such as systemic steroids and adrenocorticotrophic hormone (ACTH), are also widely accepted for other autoimmune conditions, where they can be used for maintenance or treatment of acute exacerbations. The potential disease-modifying role of ACTH in MS needs to be more extensively studied. Disease-modifying treatments for MS, such as interferon beta (IFNâ), glatiramer acetate (GA), natalizumab, fingolimod, and BG-12, have mostly unknown or insufficiently studied applications for other autoimmune conditions (with the exceptions of the BG-12 analog, which is approved for use in psoriasis, and of natalizumab, which is approved for use in Crohn’s disease). GA shows promise in inflammatory bowel disease.12

Effect of Autoimmune Comorbidities on Multiple Sclerosis Diagnosis, Treatment, and Outcomes
Comorbidities are an important issue in MS. They significantly worsen the impact of the disease and some of them (e.g., vascular disease, Alzheimer’s disease) are associated with neurodegeneration in progressive MS.13 While there are many different types of comorbidities in MS, autoimmune conditions are a common feature in many patients, and some occur more often in MS patients than in the general population.3,4,14

It has been shown that autoimmune comorbidities in MS can affect a number of aspects, including diagnosis, clinical phenotyping of the disease, disease and disability progression, quality of life, and treatment decisions.15 A North American registry study found a diagnostic delay of one to 10 years in MS patients who had vascular, autoimmune, musculoskeletal, gastrointestinal, visual, or mental comorbidities.16 No direct association has been reported between autoimmune conditions and disability progression;17 however, the association between comorbidities and increased disability at diagnosis has led to the suggestion that comorbidities may act pathophysiologically to hasten disease progression.15

The presence of autoimmune comorbidities in MS has important implications for therapeutic decision-making. For example, in the presence of comorbid inflammatory bowel disease or uveitis, the use of anti-tumour necrosis factor (TNF) biologic therapies should be avoided. Likewise, it would be inadvisable to treat MS with natalizumab in a patient previously given immunosuppressive therapy for either MS or a comorbid autoimmune condition.18

Research into the diagnosis and treatment of autoimmune comorbidities within the MS population has not been given sufficient attention. The resulting information gap adds further complexity to disease management. Addressing this gap is important, particularly because early recognition and treatment of the comorbid conditions can improve prognosis, help define the disease course, and allow better informed and more individualized treatment decisions.

Studies of Autoimmune Comorbidities in Multiple Sclerosis
Until recently, clinical data relating to the co-occurrence of autoimmune diseases in MS have been predominantly based on uncontrolled case series or small case-control studies, with few studies accounting for confounding factors such as age and sex. There are many difficulties inherent to such studies, such as selection or ascertainment bias. Results may differ depending on which conditions are included and how the diagnosis is reached.18 In ethnically-mixed populations such as that of North America, the use of spouses as controls allows ethnic matching19 (the use of such controls is fairly common in genetic studies but much less widespread in clinical trials20–22). However, since MS is significantly more prevalent in females, this approach can increase a potential gender imbalance between cases and controls.

In a study of families in which several members had been diagnosed with MS (176 families, 386 individuals with MS, and 1,107 first-degree relatives), participants were studied for a history of coexisting autoimmune disorders (see Figure 1).23 Of the 386 individuals with MS, 26 % had a coexisting autoimmune disorder. Of the 1,107 first-degree relatives, 64 % had a history of autoimmune conditions. The most commonly reported autoimmune conditions in MS patients and their relatives were Hashimoto’s thyroiditis, psoriasis, and inflammatory bowel disease (IBD).

A recent American population-based case-control study using a large database (5,296 MS cases and 26,478 matched controls) found that individuals with MS were more likely than controls to have uveitis, IBD, and Bell’s palsy prior to MS diagnosis.24 They were also more likely to develop Guillain–Barré syndrome and bullous pemphigoid. However, the study found no increased likelihood of MS patients having or developing rheumatoid arthritis (RA), lupus, or thyroiditis. The study concluded that MS may share environmental triggers, genetic susceptibilities, and/or alterations in immune homeostasis with IBD and uveitis, but not with other autoimmune disorders. The study had limitations relating to its methodology and reliance on electronic patient records. By grouping certain diseases together, opportunities to gain valuable information were lost; for example, IBD incorporates Crohn’s disease and ulcerative colitis (UC), which have immunopathological differences, and to differentiate between the two might have given clues to shared mechanisms with MS.

A Danish registry study showed that autoimmune disorders tended to co-occur with MS and to occur in MS patients’ families, but that this was not a uniform phenomenon across all diseases.25 Patients with type 1 diabetes were found to have more than a threefold increased risk of developing MS. Compared with the general Danish population, MS patients were found to have increased incidences of type 1 diabetes, UC, autoimmune thyroiditis, and pemphigoid, but a decreased incidence of RA. MS and RA appear to have a reduced likelihood of co-existence.26 This inverse association between MS and RA has also been found in a population-based cohort study using the UK General Practice Research Database.27

While the above studies show similarities, there are inconsistencies in the data regarding the association between thyroiditis and MS. Autoimmune thyroiditis was found to be significantly more prevalent in male MS patients than in male controls (9.4 versus 1.9 %; p=0.03). However, there was no significant difference in the prevalence of autoimmune thyroiditis in female MS patients and female controls (8.7 versus 9.2 %). Further studies are required to determine the cause of this increased prevalence of autoimmune thyroiditis in males with MS.28 This finding illustrates the importance of avoiding gender bias in studies of comorbidities in MS.

A large North American study found no association between MS and asthma,24 although asthma associated with chronic obstructive pulmonary disease was excluded from the study—presumably to select specifically for atopic asthma. However, a retrospective study in Wales established an inverse relationship between asthma and MS (odds ratio 0.33; 95 % confidence interval 0.15–0.77).29 This was supported by a study of general practitioner prescribing data from Wales, which found that MS patients were prescribed fewer anti-asthma drugs (e.g., bronchodilators and inhaled corticosteroids) compared with controls (but the authors noted that treatments given to MS patients could improve asthma symptoms, thus potentially reducing the need for anti-asthma medication).30 Conversely, an Australian study of 136 MS cases and 272 matched controls reported that MS patients were more likely (p=0.02) than controls to have asthma that started before the onset of MS symptoms.31 Some researchers believe that there may be a link between asthma and autoimmune conditions including MS; the detection of certain autoantibodies (e.g., antibodies to the β-2 adrenergic receptor) in asthmatics may support this.32 This link, however, is controversial, and much more data are needed to clarify putative associations and possible common mechanisms.

In summary, the data published to date show a marked association between MS and certain autoimmune comorbidities. Table 1 gives an overview of some of the more frequent autoimmune conditions and their degree of association with MS. Future studies should look at comorbidities as well as taking into account the modifying effects of socioeconomic status, ethnic origin, and cultural factors in MS.33

Autoimmune Comorbidities in Multiple Sclerosis—Genetic and Environmental Factors
Autoimmune conditions have been shown to be more common in families at high risk of multiple sclerosis than in the general population, suggesting that these diseases might arise on a genetic background of generalized susceptibility to autoimmunity.23 On the other hand, a population-based study found that, when data were adjusted for sex, no excess of common autoimmune diseases could be identified in MS patients or their families.19 Such conflicting results lead to four questions:

  • Are MS patients indeed more likely to have other autoimmune diseases?
  • Is there anything special (clinically, radiologically, immunologically, genetically) in patients with MS and autoimmune comorbidities that can help us better understand MS?
  • Are MS treatments beneficial or harmful to other autoimmune conditions?
  • Can we identify biomarkers to help us predict the outcomes of these treatments?

Studies investigating genetic susceptibility to MS have identified a number of genomic regions and specific genes of interest, most of which are associated with immune response, in particular the MHC region on chromosome 6.34–38

Although epidemiological data have suggested an inverse association between MS and RA, genome-wide association studies (GWASs) have found that MS and RA share many genetic factors.39 However, certain genetic loci for susceptibility to autoimmune disease, delineated in GWASs, are not associated with both MS and other autoimmune diseases; for example, the PTPN22 risk allele has been strongly associated with type 1 diabetes, RA, and thyroiditis, but not with MS.40

In addition to genetic factors, synergistic interactions between environmental factors that trigger autoimmunity—such as Epstein–Barr virus infection or vitamin D deficiency—may underlie comorbidities.18 Vitamin D receptor knockout and vitamin D-deficient mice have a surplus of a type of effector T-cell that has been implicated in the pathology of MS and IBD.41 In addition, smoking is associated with an increased risk of comorbid autoimmune disease in MS.3

Effects of Disease-modifying Drugs on Autoimmune Comorbidities
First-line agents approved for the treatment of MS include IFNβ and GA.42–45 Some of the autoimmune conditions more frequently associated with disease-modifying agents used in MS are shown in Table 2, and isolated cases are summarized in Table 3. These and other autoimmune comorbidities could possibly serve as biological markers predicting good response to GA and unfavourable response to IFNβ.

It is evident from Tables 2 and 3 that there are more reported cases of autoimmune comorbidities in MS patients treated with IFNβ than in those treated with GA. There have been individual case reports of exacerbation of autoimmune conditions—e.g., autoimmune hepatitis—in patients treated with GA.46 Other reported conditions that may have an autoimmune basis and are associated with GA include necrotising cutaneous lesions,47 panniculitis,48 and urticarial vasculitis.49 It must be emphasized, however, that these reports are from single case studies.

The effect of GA on autoimmune conditions comorbid to MS has been studied in experimental animal models. GA has been found to alter the clinical course of type 1 diabetes in animal models,50 and has exerted beneficial effects on uveoretinitis in rodents,51 but had no effect on rodent models of systemic lupus erythematosus (SLE)52 and was found to exacerbate RA.53 These variable results in animal models suggest that GA may exert its immunomodulatory effect in an antigen-independent manner.

As discussed above, IFNâ therapy can precipitate immune-mediated abnormalities or exacerbate an existing autoimmune tendency. Following reports of autoimmune thyroid and liver disorders in two MS patients treated with IFNâ,54 the thyroid and liver function and the serum level of 12 autoantibodies against organ-specific (thyroid, gastric, pancreatic) and non-organ-specific antigens were serially monitored. In contrast to control patients, autoantibodies (anti-nuclear, anti-smooth muscle or anti-thyroid antigens) were detected in 13 patients treated with IFNâ and, in many cases, these were associated with thyroid or liver function alteration.55 In a separate study of MS patients treated with IFNâ, serum anti-microsomal and anti-thymocyte globulin autoantibodies were detected, with one case of autoimmune hepatitis reported.56

Since these studies were completed, several major autoimmune comorbidities have been found to be associated with IFNâ treatment, including SLE,57 RA,58 UC,59 and myasthenia gravis.60 Autoimmune thyroiditis has been reported in MS patients receiving IFNâ, but not in those receiving GA.61 In 2010, we presented to the American Academy of Neurology four clinical cases of comorbid MS and psoriasis; all four patients had previously not responded to treatment with IFNâ and, later, all four responded to treatment with natalizumab.62 The association of IFNâ treatment with systemic autoimmune diseases may be explained in several ways. IFNâ modulates gene expression and the immune system, providing pathogenic influences in some cases, while in other cases providing protection.63

Recent studies have enhanced our understanding of the role of T-helper type 1 (Th1) and T-helper type 17 (Th17) effector cells. A growing body of evidence suggests that Th17 cells, along with Th1 cells, play a major role in the pathogenesis of MS.64 Th1 and Th17 responses counter-regulate each other. Both Th1 and Th17 cells have the capacity to cause autoimmunity independently of each other. These findings are important in understanding the role of IFNâ in the treatment of MS and MS-associated comorbidities. In animal model studies, it was found that treatment with IFNâ reduced EAE symptoms induced by Th1 cells, but exacerbated symptoms induced by Th17 cells. Furthermore, non-responsiveness to IFNâ in patients with relapsing-remitting multiple sclerosis (RRMS) was associated with high serum levels of the TH17 cytokine IL-17F.65 High serum levels of IL-7, particularly when paired with low serum levels of IL-17F, are predictive of response to IFNâ.66 IFNâ and other type I IFNs appear to be immunomodulatory in diseases driven predominantly by Th1, but inflammatory in diseases resulting from a Th17 response.67

Summary and Future Directions
Autoimmune comorbidities are an important component of the range of comorbid conditions seen in MS and contribute to the substantial disease burden experienced by many MS patients. Autoimmune comorbidities are often associated with MS and can worsen the impact of the disease. These conditions need to be treated and managed by neurologists and specialist MS nurses in collaboration with other specialists.

It is important to be aware that the predisposition of MS patients to autoimmune comorbidities is not uniform across all diseases. Further studies are required to establish which genetic and environmental factors influence autoimmune comorbidities in MS. More standardized methods of measuring and analysing autoimmune comorbidities and their associations with MS are needed. More studies are also needed to address the effects of autoimmune comorbidities on MS. These future studies should assess a wider range of comorbidities and examine how the frequency of comorbidities changes over time. Finally, the effects of MS treatments on autoimmune comorbidities can potentially inform choices about therapeutic regimens, and more research in this area is greatly needed.

Article Information:
Disclosure

Regina Berkovich, MD, PhD, has served as a consultant on advisory boards for Acorda, Bayer, Biogen Idec, Questcor, and Teva, and has received research support from Biogen Idec, Questcor, Teva, and the National Multiple Sclerosis Society. Dawood Subhani, MBBS, and Lawrence Steinman, MD, have no conflicts of interest to declare. Acknowledgments: Editorial assistance was provided by Touch Briefings.

Correspondence

Regina Berkovich, MD, PhD, University of Southern California MS Comprehensive Care Center and Research Group, Healthcare Consultation Center II, 1520 San Pablo St., Suite 3000, Los Angeles, CA 90033. E: rberkovi@usc.edu

Received

2012-02-06T00:00:00

References

  1. Behan PO, Geschwind N, Lamarche JB, et al., Delayed hypersensitivity to encephalitogenic protein in disseminated encephalomyelitis, Lancet, 1968;2:1009–12.
  2. Behan PO, Kies MW, Lisak RP, et al., Immunologic mechanisms in experimental encephalomyelitis in nonhuman primates, Arch Neurol, 1973;29:4–9.
  3. Marrie RA, Horwitz RI, Cutter G, et al., Smokers with multiple sclerosis are more likely to report comorbid autoimmune diseases, Neuroepidemiology, 2011;36:85–90.
  4. Somers EC, Thomas SL, Smeeth L, et al., Autoimmune diseases co-occurring within individuals and within families: a systematic review, Epidemiology, 2006;17:202–17.
  5. Sriram S, Steiner I, Experimental allergic encephalomyelitis: a misleading model of multiple sclerosis, Ann Neurol, 2005;58:939–45.
  6. Steinman L, Zamvil SS, How to successfully apply animal studies in experimental allergic encephalomyelitis to research on multiple sclerosis, Ann Neurol, 2006;60:12–21.
  7. Steinman L, Blocking adhesion molecules as therapy for multiple sclerosis: natalizumab, Nat Rev Drug Discov, 2005;4:510–8.
  8. Steinman L, Merrill JT, McInnes IB, Peakman M, Optimization of current and future therapy for autoimmune diseases, Nat Med, 2012;18:59–65.
  9. Owens GP, Bennett JL, Lassmann H, et al., Antibodies produced by clonally expanded plasma cells in multiple sclerosis cerebrospinal fluid, Ann Neurol, 2009;65:639–49.
  10. Kanter JL, Narayana S, Ho PP, et al., Lipid microarrays identify key mediators of autoimmune brain inflammation, Nat Med, 2006;12:138–43.
  11. Nakahara J, Aiso S, Suzuki N, Autoimmune versus oligodendrogliopathy: the pathogenesis of multiple sclerosis, Arch Immunol Ther Exp (Warsz), 2010;58:325–33.
  12. Yablecovitch D, Shabat-Simon M, Aharoni R, et al., Beneficial effect of glatiramer acetate treatment on syndecan-1 expression in dextran sodium sulfate colitis, J Pharmacol Exp Ther, 2011;337:391–9.
  13. Frischer JM, Bramow S, Dal-Bianco A, et al., The relation between inflammation and neurodegeneration in multiple sclerosis brains, Brain, 2009;132:1175–89.
  14. Broadley SA, Deans J, Sawcer SJ, et al., Autoimmune disease in first-degree relatives of patients with multiple sclerosis. A UK survey, Brain, 2000;123:1102–11.
  15. Marrie RA, Horwitz R, Cutter G, Tyry T, Cumulative impact of comorbidity on quality of life in MS, Acta Neurol Scand, 2012; 125:180–6.
  16. Marrie RA, Horwitz R, Cutter G, et al., Comorbidity delays diagnosis and increases disability at diagnosis in MS, Neurology, 2009;72:117–24.
  17. Kirby S, Brown MG, Murray TJ, et al., Progression of multiple sclerosis in patients with other autoimmune diseases, Mult Scler, 2005;11:S28–S9 P128.
  18. Constantinescu CS, Gran B, Multiple sclerosis: autoimmune associations in multiple sclerosis, Nat Rev Neurol, 2010;6:591–2.
  19. Ramagopalan SV, Dyment DA, Valdar W, et al., Canadian Collaborative Study Group, Autoimmune disease in families with multiple sclerosis: a population-based study, Lancet Neurol, 2007;6:604–10.
  20. Elbein SC, Wegner K, Miles C, et al., The role of late-onset autoimmune diabetes in white familial NIDDM pedigrees, Diabetes Care, 1997;20:1248–51.
  21. Fingerlin TE, Erdos MR, Watanabe RM, et al., Variation in three single nucleotide polymorphisms in the calpain-10 gene not associated with type 2 diabetes in a large Finnish cohort, Diabetes, 2002;51:1644–8.
  22. Wacholder S, Silverman DT, McLaughlin JK, Mandel JS, Selection of controls in case-control studies. II. Types of controls, Am J Epidemiol, 1992;135:1029–41.
  23. Barcellos LF, Kamdar BB, Ramsay PP, et al., Clustering of autoimmune diseases in families with a high-risk for multiple sclerosis: a descriptive study, Lancet Neurol, 2006;5:924–31.
  24. Langer-Gould A, Albers KB, Van Den Eeden SK, Nelson LM, Autoimmune diseases prior to the diagnosis of multiple sclerosis: a population-based case-control study, Mult Scler, 2010;16:855–61.
  25. Nielsen NM, Westergaard T, Frisch M, et al., Type 1 diabetes and multiple sclerosis: A Danish population-based cohort study, Arch Neurol, 2006;63:1001–4.
  26. Cooper GS, Bynum ML, Somers EC, Recent insights in the epidemiology of autoimmune diseases: improved prevalence estimates and understanding of clustering of diseases, J Autoimmun, 2009;33:197–207.
  27. Somers EC, Thomas SL, Smeeth L, Hall AJ, Are individuals with an autoimmune disease at higher risk of a second autoimmune disorder?, Am J Epidemiol, 2009;169:749–55.
  28. Niederwieser G, Buchinger W, Bonelli RM, et al., Prevalence of autoimmune thyroiditis and non-immune thyroid disease in multiple sclerosis, J Neurol, 2003;250:672–5.
  29. Tremlett HL, Evans J, Wiles CM, Luscombe DK, Asthma and multiple sclerosis: an inverse association in a case-control general practice population, QJM, 2002;95:753–6.
  30. Evans J, Rogers C, Wiles CM, et al., General practitionersf prescribing data for multiple sclerosis patients indicates a link with asthma, Br J Gen Pract, 2000;50:323.4.
  31. Ponsonby AL, Dwyer T, van der Mei I, et al., Asthma onset prior to multiple sclerosis and the contribution of sibling exposure in early life, Clin Exp Immunol, 2006;146:463.70.
  32. Zweiman B, Asthma and autoimmunity: is there a connection?, Curr Allergy Asthma Rep, 2007;7:157-8.
  33. Marrie RA, Horwitz RI, Emerging effects of comorbidities on multiple sclerosis, Lancet Neurol, 2010;9:820.8.
  34. Caillier SJ, Briggs F, Cree BA, et al., Uncoupling the roles of HLA-DRB1 and HLA-DRB5 genes in multiple sclerosis, J Immunol, 2008;181:5473.80.
  35. Australia and New Zealand Multiple Sclerosis Genetics Consortium (ANZgene), Genome-wide association study identifies new multiple sclerosis susceptibility loci on chromosomes 12 and 20, Nat Genet, 2009;41:824.8.
  36. Dyment DA, Herrera BM, Cader MZ, et al., Complex interactions among MHC haplotypes in multiple sclerosis: susceptibility and resistance, Hum Mol Genet, 2005;14:2019.26.
  37. Fernando MM, Stevens CR, Walsh EC, et al., Defining the role of the MHC in autoimmunity: a review and pooled analysis, PLoS Genet, 2008;4:e1000024.
  38. Zuvich RL, McCauley JL, Pericak-Vance MA, Haines JL, Genetics and pathogenesis of multiple sclerosis, Semin Immunol, 2009;21:328.33.
  39. Suzuki A, Kochi Y, Okada Y, Yamamoto K, Insight from genome-wide association studies in rheumatoid arthritis and multiple sclerosis, FEBS Lett, 2011;585:3627.32.
  40. Criswell LA, Pfeiffer KA, Lum RF, et al., Analysis of families in the multiple autoimmune disease genetics consortium (MADGC) collection: the PTPN22 620W allele associates with multiple autoimmune phenotypes, Am J Hum Genet, 2005;76:561.71.
  41. Cantorna MT, Vitamin D, multiple sclerosis and inflammatory bowel disease, Arch Biochem Biophys, 2011;November 10 [Epub ahead of print].
  42. Freedman MS, Hughes B, Mikol DD, et al., Efficacy of disease-modifying therapies in relapsing remitting multiple sclerosis: a systematic comparison, Eur Neurol, 2008;60:1.11.
  43. Goldberg LD, Edwards NC, Fincher C, et al., Comparing the cost-effectiveness of disease-modifying drugs for the first-line treatment of relapsing-remitting multiple sclerosis, J Manag Care Pharm, 2009;15:543.55.
  44. Stuart WH, Clinical management of multiple sclerosis: the treatment paradigm and issues of patient management, J Manag Care Pharm, 2004;10:S19.25.
  45. Tsang BK, Macdonell R, Multiple sclerosis- diagnosis,management and prognosis, Aust Fam Physician, 2011;40:94.55.
  46. Neumann H, Csepregi A, Sailer M, Malfertheiner P, Glatiramer acetate induced acute exacerbation of autoimmune hepatitis in a patient with multiple sclerosis, J Neurol, 2007;254:816.7.
  47. Bosca I, Bosca M, Belenguer A, et al., Necrotising cutaneous lesions as a side effect of glatiramer acetate, J Neurol, 2006;253:1370.1.
  48. Soos N, Shakery K, Mrowietz U, Localized panniculitis and subsequent lipoatrophy with subcutaneous glatiramer acetate (Copaxone) injection for the treatment of multiple sclerosis, Am J Clin Dermatol, 2004;5:357.9.
  49. Cicek D, Kandi B, Oguz S, et al., An urticarial vasculitis case induced by glatiramer acetate, J Dermatolog Treat, 2008;19:305.7.
  50. Cui G, Zhang Y, Gong Z, et al., Induction of CD4+CD25+Foxp3+ regulatory T cell response by glatiramer acetate in type 1 diabetes, Cell Res, 2009;19:574.83.
  51. Zhang M, Chan CC, Vistica B, et al., Copolymer 1 inhibits experimental autoimmune uveoretinitis, J Neuroimmunol, 2000;103:189.94.
  52. Borel P, Benkhoucha M, Weber MS, et al., Glatiramer acetate treatment does not modify the clinical course of (NZB x BXSB)F1 lupus murine model, Int Immunol, 2008;20:1313.9.
  53. Zheng B, Switzer K, Marinova E, et al., Exacerbation of autoimmune arthritis by copolymer-I through promoting type 1 immune response and autoantibody production, Autoimmunity, 2008;41:363.71.
  54. Durelli L, Bongioanni MR, Ferrero B, et al., Interferon treatment for multiple sclerosis: autoimmune complications may be lethal, Neurology, 1998;50:570.1.
  55. Durelli L, Ferrero B, Oggero A, et al., Autoimmune events during interferon beta-1b treatment for multiple sclerosis, J Neurol Sci, 1999;162:74.83.
  56. Speciale L, Saresella M, Caputo D, et al., Serum auto antibodies presence in multiple sclerosis patients treated with beta-interferon 1a and 1b, J Neurovirol, 2000;6(Suppl. 2):S57.61.
  57. Borg FA, Isenberg DA, Syndromes and complications of interferon therapy, Curr Opin Rheumatol, 2007;19:61.6.
  58. Alsalameh S, Manger B, Kern P, Kalden J, New onset of rheumatoid arthritis during interferon beta-1B treatment in a patient with multiple sclerosis: comment on the case report by Jabaily and Thompson, Arthritis Rheum, 1998;41:754.
  59. Schott E, Paul F, Wuerfel JT, et al., Development of ulcerative colitis in a patient with multiple sclerosis following treatment with interferon beta 1a, World J Gastroenterol, 2007;13:3638.40.
  60. Blake G, Murphy S, Onset of myasthenia gravis in a patient with multiple sclerosis during interferon-1b treatment, Neurology, 1997;49:1747.8.
  61. Rotondi M, Stufano F, Lagonigro MS, et al., Interferon-ƒÀ but not Glatiramer acetate stimulates CXCL10 secretion in primary cultures of thyrocytes: a clue for understanding the different risks of thyroid dysfunctions in patients with multiple sclerosis treated with either of the two drugs, J Neuroimmunol, 2011;234:161.4.
  62. Berkovich RR, Four Cases of Comorbid Multiple Sclerosis and Psoriasis: Sustained Remission of Both Conditions While on Natalizumab, Presented at: American Academy of Neurology 62nd Meeting, Toronto, Canada, April 10.17, 2010;Abstract: P06.163.
  63. Crow MK, Type I interferon in organ-targeted autoimmune and inflammatory diseases, Arthritis Res Ther, 2010;12(Suppl. 1):S5.
  64. Chen SJ, Wang YL, Fan HC, et al., Current status of the immunomodulation and immunomediated therapeutic strategies for multiple sclerosis, Clin Dev Immunol, 2012;2012:970789.
  65. Axtell RC, de Jong BA, Boniface K, et al., T helper type 1 and 17cells determine efficacy of interferon-beta in multiple sclerosis and experimental encephalomyelitis, Nat Med, 2010;16:406.12.
  66. Lee LF, Axtell R, Tu GH, et al., IL-7 promotes T(H)1 development and serum IL-7 predicts clinical response to interferon-ƒÀ inmultiple sclerosis, Sci Transl Med, 2011;3:93ra68.
  67. Axtell RC, Raman C, Steinman L, Type I interferons: beneficial in Th1 and detrimental in Th17 autoimmunity, Clin Rev Allergy Immunol, 2012;January 10 [Epub ahead of print].
  68. Deltenre P, Peny MO, Dufour A, et al., Acute hepatitis induced by glatiramer acetate, BMJ Case Rep, 2009;2009. pii: bcr09.2008.0913.
  69. Von Kalckreuth V, Lohse AW, Schramm C, Unmasking autoimmune hepatitis under immunomodulatory treatment of multiple sclerosis.not only beta interferon, Am J Gastroenterol, 2008;103:2147.8; author reply 2148.
  70. Flachenecker P, Autonomic dysfunction in Guillain-Barre syndrome and multiple sclerosis, J Neurol, 2007; 254(Suppl. 2):II96.101.
  71. De Jager PL, Graham R, Farwell L, et al., The role of inflammatory bowel disease susceptibility loci in multiple sclerosis and systemic lupus erythematosus, Genes Immun, 2006;7:327.34.
  72. Pokorny CS, Beran RG, Pokorny MJ, Association between ulcerative colitis and multiple sclerosis, Intern Med J, 2007;37:721.4.
  73. Jawad SH, Askari A, Ward AB, Case history of a patient with multiple sclerosis and scleroderma, Br J Rheumatol, 1997;36:502.3.
  74. Trostle DC, Helfrich D, Medsger TA Jr., Systemic sclerosis (scleroderma) and multiple sclerosis, Arthritis Rheum, 1986;29:124.7.
  75. Marrosu MG, Cocco E, Lai M, et al., Patients with multiple sclerosis and risk of type 1 diabetes mellitus in Sardinia, Italy: a cohort study, Lancet, 2002;359:1461.5.
  76. Becker MD, Heiligenhaus A, Hudde T, et al., Interferon as a treatment for uveitis associated with multiple sclerosis, Br J Ophthalmol, 2005;89:1254.7.
  77. Kwok T, Jing Loo W, Guenther L, Psoriasis and multiple sclerosis: is there a link?, J Cutan Med Surg, 2010;14:151.5.
  78. Dionisiotis J, Zoukos Y, Thomaides T, Development of myasthenia gravis in two patients with multiple sclerosis following interferon beta treatment, J Neurol Neurosurg Psychiatry, 2004;75:1079.
  79. Gharagozli K, Shojaei M, Harandi AA, et al., Myasthenia gravis development and crisis subsequent to multiple sclerosis, Case Report Med, 2011;2011:291731.
  80. Ball NJ, Cowan BJ, Hashimoto SA, Lobular panniculitis at the site of subcutaneous interferon beta injections for the treatment of multiple sclerosis can histologically mimic pancreatic panniculitis. A study of 12 cases, J Cutan Pathol, 2009;36:331.7.
  81. Poulin F, Rico P, Cote J, Begin LR, Interferon beta-induced panniculitis mimicking acute appendicitis, Arch Dermatol, 2009;145:916.7.
  82. Soares Almeida LM, Requena L, Kutzner H, et al., Localized panniculitis secondary to subcutaneous glatiramer acetate injections for the treatment of multiple sclerosis: a clinicopathologic and immunohistochemical study, J Am Acad Dermatol, 2006;55:968.74.
  83. Lopez-Lerma I, Iranzo P, Herrero C, New-onset psoriasis in a patient treated with interferon beta-1a, Br J Dermatol, 2009;160:716.7.
  84. La Mantia L, Capsoni F, Psoriasis during interferon beta treatment for multiple sclerosis, Neurol Sci, 2010;31:337.9.
  85. Navne JE, Hedegaard U, Bygum A, [Activation of psoriasis in patients undergoing treatment with interferon-beta], Ugeskr Laeger, 2005;167:2903.4.
  86. Rodrigues S, Magro F, Soares J, et al., Case series: ulcerative colitis, multiple sclerosis, and interferon-beta 1a, Inflamm Bowel Dis, 2010;16:2001.3.
  87. Tuna Y, Basar O, Dikici H, Koklu S, Rapid onset of ulcerative colitis after treatment with interferon ƒÀ1a in a patient with multiple sclerosis, J Crohns Colitis, 2011;5:75.6.
  88. Palao-Duarte S, Corral-Corral I, Zarza B, Costa-Frossard L, [Ulcerative colitis in a female patient with multiple sclerosis receiving treatment with interferon], Rev Neurol, 2005;41:319.20.
  89. Daza-Barriga JS, [Small vessel vasculitis associated with the use of interferon beta-1a in multiple sclerosis], Rev Neurol, 2008;46:702.3.
  90. Debat Zoguereh D, Boucraut J, Beau-Salinas F, et al., [Cutaneous vasculitis with renal impairment complicating interferon-beta 1a therapy for multiple sclerosis], Rev Neurol (Paris), 2004;160:1081.4.
  91. Szilasiova J, Gdovinova Z, Jautova J, et al., Cutaneous vasculitis associated with interferon beta-1b treatment for multiple sclerosis, Clin Neuropharmacol, 2009;32:301.3.
  92. Bonaci-Nikolic B, Jeremic I, Andrejevic S, et al., Anti-double stranded DNA and lupus syndrome induced by interferon-beta therapy in a patient with multiple sclerosis, Lupus, 2009;18:78.80.

Further Resources

Share this Article
Related Content In Multiple Sclerosis
  • Copied to clipboard!
    accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-whiteticktimetranscriptup-arrowwebinar Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72